Literature DB >> 17159010

Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease.

Dietrich Rothenbacher1, Wolfgang Koenig, Hermann Brenner.   

Abstract

BACKGROUND: The purpose of this study was to investigate the prognostic role of N-terminal pro-B-natriuretic peptide (NT-proBNP) serum level compared with C-reactive protein (CRP) level and creatinine clearance (CrCl) for the subsequent risk of cardiovascular events in a large cohort of patients with stable coronary heart disease (CHD).
METHODS: Serum concentrations of NT-proBNP and CRP and CrCl were measured at baseline in a cohort of 1051 patients aged 30 to 70 years with CHD. The Cox proportional hazards model was used to determine the prognostic value of NT-proBNP, CRP, and CrCl on a combined cardiovascular disease (CVD) end point (fatal and nonfatal myocardial infarction and stroke).
RESULTS: During follow-up (mean of 48.7 months), 95 patients (9.0%) experienced a secondary CVD event. Patients in the top quartile of the NT-proBNP distribution at baseline had a hazard ratio (HR) of 3.34 (95% confidence interval [CI], 1.74-6.45) for subsequent secondary CVD events compared with those in the bottom quartile (P for trend <.001) after controlling for age, sex, smoking status, history of diabetes mellitus, initial management of CHD, rehabilitation clinic, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and treatment with lipid-lowering drugs. For CRP, the corresponding HR was 1.76 (95% CI, 0.96-3.24) (P value for trend, .06). Patients with CrCl levels lower than 60 mL/min had an HR of 2.39 (95% CI, 1.06-5.40) compared with patients with a CrCl of 90 mL/min or higher (P for trend, .002). If all 3 markers were included simultaneously in 1 model, NT-proBNP still showed predictive ability for recurrent CVD events.
CONCLUSION: N-terminal proBNP may be a clinically useful marker weeks after an acute coronary event and may provide complementary prognostic information to established risk determinants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17159010     DOI: 10.1001/archinte.166.22.2455

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  16 in total

1.  Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.

Authors:  Bob Siegerink; Renke Maas; Carla Y Vossen; Edzard Schwedhelm; Wolfgang Koenig; Rainer Böger; Dietrich Rothenbacher; Hermann Brenner; Lutz P Breitling
Journal:  Clin Res Cardiol       Date:  2012-10-17       Impact factor: 5.460

2.  Does Information on Blood Heavy Metals Improve Cardiovascular Mortality Prediction?

Authors:  Xin Wang; Bhramar Mukherjee; Sung Kyun Park
Journal:  J Am Heart Assoc       Date:  2019-10-19       Impact factor: 5.501

3.  Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial.

Authors:  Adriano Caixeta; Gregg W Stone; Roxana Mehran; Edwin A Lee; Brent T McLaurin; David A Cox; Michel E Bertrand; A Michael Lincoff; Jeffrey W Moses; Harvey D White; E Magnus Ohman; Tullio Palmerini; George Syros; Christos Kittas; Martin Fahy; W Craig Hooper; Alexandra J Lansky; George D Dangas
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

4.  Do High-sensitivity Troponin and Natriuretic Peptide Predict Death or Serious Cardiac Outcomes After Syncope?

Authors:  Carol L Clark; Thomas A Gibson; Robert E Weiss; Annick N Yagapen; Susan E Malveau; David H Adler; Aveh Bastani; Christopher W Baugh; Jeffrey M Caterino; Deborah B Diercks; Judd E Hollander; Bret A Nicks; Daniel K Nishijima; Manish N Shah; Kirk A Stiffler; Alan B Storrow; Scott T Wilber; Benjamin C Sun
Journal:  Acad Emerg Med       Date:  2019-03-04       Impact factor: 3.451

5.  NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.

Authors:  Nisha Bansal; Ronit Katz; Lorien Dalrymple; Ian de Boer; Christopher DeFilippi; Bryan Kestenbaum; Meyeon Park; Mark Sarnak; Stephen Seliger; Michael Shlipak
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-20       Impact factor: 8.237

6.  The impact of renal function on the prognostic value of N-terminal pro-B-type natriuretic peptide in patients with coronary artery disease.

Authors:  Fei Chen; Jia-Qi Li; Yuan-Wei-Xiang Ou; Tian-Li Xia; Fang-Yang Huang; Hua Chai; Bao-Tao Huang; Qiao Li; Xiao-Bo Pu; Guo-Yong Li; Yong Peng; Mao Chen; De-Jia Huang
Journal:  Cardiol J       Date:  2018-04-03       Impact factor: 2.737

7.  Biomarkers to predict recurrent cardiovascular disease: the Heart and Soul Study.

Authors:  Michael G Shlipak; Joachim H Ix; Kirsten Bibbins-Domingo; Feng Lin; Mary A Whooley
Journal:  Am J Med       Date:  2008-01       Impact factor: 4.965

8.  Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study.

Authors:  Lutz P Breitling; Wolfgang Koenig; Marcus Fischer; Ziad Mallat; Christian Hengstenberg; Dietrich Rothenbacher; Hermann Brenner
Journal:  PLoS One       Date:  2011-07-22       Impact factor: 3.240

9.  B-type natriuretic peptide and high sensitive C-reactive protein predict 2-year all cause mortality in chest pain patients: a prospective observational study from Salta, Argentina.

Authors:  Ricardo León de la Fuente; Patrycja A Naesgaard; Stein Tore Nilsen; Leik Woie; Torbjoern Aarsland; Patricio Gallo; Heidi Grundt; Harry Staines; Dennis W T Nilsen
Journal:  BMC Cardiovasc Disord       Date:  2011-09-29       Impact factor: 2.298

10.  B-type natriuretic peptide is a long-term predictor of all-cause mortality, whereas high-sensitive C-reactive protein predicts recurrent short-term troponin T positive cardiac events in chest pain patients: a prognostic study.

Authors:  Trygve Brügger-Andersen; Volker Pönitz; Harry Staines; David Pritchard; Heidi Grundt; Dennis W T Nilsen
Journal:  BMC Cardiovasc Disord       Date:  2008-11-25       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.